Explore how single nucleotide polymorphisms (SNPs) influence non-small cell lung cancer risk, treatment response, and personalized medicine approaches.
Learn about the revolutionary HRD assay for endometrial cancer that personalizes treatment by assessing DNA repair competency.
Discover how the ABTB2 regulatory variant rs6484711 predicts epirubicin-based chemotherapy response in Luminal A breast cancer patients.
Discover how pharmacogenomics uses your genetic blueprint to personalize medication, improving efficacy and reducing side effects.
Explore how next-generation sequencing is transforming pharmacogenetics and enabling personalized medicine through comprehensive DNA analysis.
Revolutionary genomic technologies are illuminating the 'dark matter' of human DNA, uncovering variations that explain disease disparities and evolutionary history.